Niacin (Nicotinic Acid).

The flushing form is nicotinic acid itself, so any additional niacin in a formula adds to the same total. Skin flushing tracks that combined dose, not either entry alone.

About 60 mg of tryptophan converts to 1 mg of niacin equivalents through the kynurenine pathway. Supplying nicotinic acid spares tryptophan for its other uses, and supplying tryptophan adds to niacin status.

Kynureninase, the step that converts tryptophan toward niacin, is a pyridoxal-phosphate enzyme. Without B6 the tryptophan route to niacin stalls and dietary nicotinic acid carries the whole load.

Kynurenine monooxygenase in the tryptophan-to-niacin pathway is FAD-dependent. Riboflavin status therefore sets how much niacin the body can make for itself.

Excess nicotinic acid is cleared by methylation to N-methylnicotinamide, which draws on S-adenosylmethionine. Trimethylglycine restores methyl groups so the methylation cycle is not depleted at higher intakes.

Niacin clearance consumes methyl groups, and methylfolate feeds the cycle that regenerates them through methionine synthase. The two move in opposite directions on the same methyl pool.

Methionine synthase needs B12 to hand folate-derived methyl groups back into the cycle that niacin methylation draws down. Adequate B12 keeps that recycling intact.

The warm skin flush comes from prostaglandin D2 released by dermal Langerhans cells. Salicylates from willow bark blunt that prostaglandin step, which is the long-standing way formulators soften the sensation.

Nicotinic acid enters the NAD pool through the Preiss-Handler route. Adding NAD or its precursors to the same formula raises one pool by two paths.

Nicotinamide riboside is salvaged into NAD without the flushing receptor step that nicotinic acid triggers. Both raise the same dinucleotide pool by different entry points.

Monacolin K is chemically the same molecule as lovastatin, and the nicotinic acid plus statin pairing is settled pharmacology with additive effects on normal lipid handling and on muscle-related tolerance. A formula holding both is combining two active lipid-pathway agents.

Chromium in glucose tolerance factor preparations is commonly supplied as a nicotinate complex, so it carries niacin with it. Both also act on normal glucose handling, in opposing directions at higher nicotinic acid intakes.

Nicotinic acid and nicotinamide are two chemical forms of vitamin B3 that both feed the salvage route to NAD and NADP. Nicotinamide does not engage GPR109A on dermal immune cells, so it carries no flush response. Formulators pair or substitute them depending on whether the flush is wanted as a felt cue. The two are not interchangeable for the lipid-handling effects reported with the acid form.

Nicotinic acid enters NAD synthesis through the Preiss-Handler route via nicotinic acid mononucleotide. NMN enters one step further along, downstream of the rate-limiting NAMPT step. Because the entry points differ, the two do not compete for the same enzyme, which is the mechanistic argument for combining them. Whether the combination raises tissue NAD more than either alone has not been shown in human trials.

The so-called flush-free form of B3 is nicotinic acid esterified to inositol. Slow hydrolysis releases free nicotinic acid at a low rate, which is why the flush is muted. The same slow release means blood levels of free nicotinic acid stay lower than with the immediate-release acid. Read the pairing as a delivery choice rather than an added benefit.

The body makes a portion of its own niacin from dietary tryptophan, at roughly one part niacin from sixty parts tryptophan. The opening step runs on a heme-containing dioxygenase, so iron status sits upstream of endogenous niacin supply. Low iron status slows that conversion and shifts more of the requirement onto dietary intake. This is settled biochemistry rather than a tested supplement combination.

Disposal of surplus vitamin B3 runs through methylation, and each molecule methylated spends one S-adenosylmethionine. High intakes therefore draw on the same methyl pool that supports other methyltransferase reactions. N1-methylnicotinamide appears in the co-study record as a recognised niacin metabolite. The interaction is mechanistic and dose dependent, not an effect demonstrated in a combination trial.

Methionine is adenosylated to form SAM, the methyl donor spent when nicotinamide is methylated for excretion. Sustained high B3 intake increases that methylation load. Adequate methionine and the folate and B12 cycle that regenerates it keep the pool replenished. The relationship is pharmacological rather than a tested pairing.

Coenzyme A carries acetyl groups into the citric acid cycle while NAD accepts the electrons released there. Neither carrier does useful work without the other being present. B-complex products pair them for that reason. This is textbook energy metabolism, not a claim that the pair outperforms either alone.

Nicotinic acid reduces fatty acid release from fat tissue by acting on GPR109A, which lowers the substrate reaching the liver for triglyceride assembly. Marine omega-3 fatty acids act inside the liver on triglyceride synthesis and clearance. Because the points of action differ, the two support normal blood lipid levels by non-overlapping routes. Combination outcome data in people is not something this candidate set contains.

Sterols compete with dietary cholesterol for space in mixed micelles, so less is absorbed. Nicotinic acid works systemically on fat tissue and hepatic lipoprotein assembly. The separation of compartments is the reason the two are combined in lipid-support formulas. No combination trial appears in this ingredient's candidate literature.

Psyllium forms a gel that carries bile acids out in stool, prompting the liver to draw on circulating cholesterol to make more. Nicotinic acid does not act in the lumen at all. Combining a luminal and a systemic route is ordinary formulation logic for lipid support. Fibre can also slow the absorption of anything taken at the same time, so spacing matters.

Berberine acts on AMPK signalling and hepatic LDL receptor expression. Nicotinic acid acts on adipocyte GPR109A and downstream substrate supply. The two are combined for that separation rather than for any measured joint effect. Berberine also affects several drug-metabolising enzymes, which is a reason to space it from other actives.

Skin flushing after nicotinic acid follows a burst of prostaglandin D2 from Langerhans cells, and prostaglandin D2 sits high in the co-study record for this ingredient. Quercetin inhibits cyclooxygenase-dependent prostaglandin formation in cell systems. Whether that translates into a milder flush in people has not been measured. Read this as mechanistic reasoning, not a tested pairing.

Aged garlic constituents act on hepatic cholesterol synthesis enzymes in laboratory work. Nicotinic acid acts on fat tissue lipolysis. The pairing is formulation convention rather than a combination with joint outcome data. Garlic preparations also have mild platelet effects worth noting alongside other blood-thinning actives.